ValiRx plc (LSE:VAL) announced that its subsidiary, Inaphaea Limited, has partnered with TwinEdge Bioscience to accelerate cancer drug development using digital ‘patient avatars’ powered by AI and computational biology. This collaboration seeks to create one of the largest populations of digital twins, aiming to reduce clinical trial costs and improve patient-drug matching.
Inaphaea is also enhancing its capabilities through agreements for new cancer cell models and the 3K Screen program, which has already identified promising drug candidates for further testing and potential commercialization.
While the company continues to make strategic scientific progress, financial performance remains challenging, with significant losses and dependence on external funding. Technical indicators show a neutral to slightly positive outlook, but the overall valuation is impacted by unprofitability.
About ValiRx
ValiRx plc is a life sciences company focused on early-stage cancer therapeutics and women’s health. The firm aims to translate innovative scientific research into effective medicines, providing a framework to accelerate clinical development and improve patient outcomes.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply